Adult Acute Leukemia

Disease-a-Month

Volumn 58, Issue 4, 2012, Pages 219-238

  Cornell, Robert Frank ^a   Palmer, Jeanne ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARSENIC TRIOXIDE; ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DASATINIB; DAUNORUBICIN; GLUCOCORTICOID; IMATINIB; MERCAPTOPURINE; METHOTREXATE; NILOTINIB; RETINOIC ACID; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; CHROMOSOME TRANSLOCATION; GENETIC ASSOCIATION; HUMAN; LOW DRUG DOSE; MAINTENANCE THERAPY; MOLECULAR GENETICS; OVERALL SURVIVAL; PROMYELOCYTIC LEUKEMIA;

ADULT; AGE FACTORS; ANEMIA; ANTINEOPLASTIC AGENTS; CCAAT-ENHANCER-BINDING PROTEINS; CORE BINDING FACTOR ALPHA 2 SUBUNIT; DIPLOIDY; DISSEMINATED INTRAVASCULAR COAGULATION; FMS-LIKE TYROSINE KINASE 3; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEPATOMEGALY; HUMANS; KARYOTYPE; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; LEUKOCYTE COUNT; LEUKOSTASIS; LYMPHATIC DISEASES; MUTATION; NUCLEAR PROTEINS; PANCYTOPENIA; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ETS; REPRESSOR PROTEINS; RISK FACTORS; SPINAL PUNCTURE; SPLENOMEGALY; THROMBOCYTOPENIA; TRANSLOCATION, GENETIC;

EID: 84858835003     PISSN: 00115029     EISSN: 15578194     Source Type: Journal    
DOI: 10.1016/j.disamonth.2012.01.011     Document Type: Article

References (90)

1. Jemal A., Siegel R., Xu J., et al. Cancer statistics. CA Cancer J Clin 2010, 2010(60):277-300.
2. Juliusson G., Antunovic P., Derolf A., et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish acute leukemia registry. Blood 2009, 113:4179-4187.
3. Vardiman J.W., Thiele J., Arber D.A., et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009, 114:937-951.
4. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976, 33:451-458.
5. Levine E.G., Bloomfield C.D. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol 1992, 19:47-84.
6. Austin H., Delzell E., Cole P. Benzene and leukemia. A review of the literature and a risk assessment. Am J Epidemiol 1988, 127:419-439.
7. Song W.J., Sullivan M.G., Legare R.D., et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet 1999, 23:166-175.
8. Taylor A.M., Metcalfe J.A., Thick J., et al. Leukemia and lymphoma in ataxia telangiectasia. Blood 1996, 87:423-438.
9. Rosner F. Acute leukemia in Down's syndrome. N Engl J Med 1976, 295:1319.
10. Leone G., Mele L., Pulsoni A., et al. The incidence of secondary leukemias. Haematologica 1999, 84:937-945.
11. Le Beau M.M., Albain K.S., Larson R.A., et al. Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 1986, 4:325-345.
12. Thirman M.J., Gill H.J., Burnett R.C., et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993, 329:909-914.
13. Ratnam K.V., Khor C.J., Su W.P. Leukemia cutis. Dermatol Clin 1994, 12:419-431.
14. Cassileth P.A., Sylvester L.S., Bennett J.M., et al. High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. J Clin Oncol 1988, 6:495-498.
15. Vardiman J.W., Harris N.L., Brunning R.D. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002, 100:2292-2302.
16. Campos L., Guyotat D., Archimbaud E., et al. Surface marker expression in adult acute myeloid leukaemia: correlations with initial characteristics, morphology and response to therapy. Br J Haematol 1989, 72:161-166.
17. Slovak M.L., Kopecky K.J., Cassileth P.A., et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 2000, 96:4075-4083.
18. Grimwade D., Moorman A., Hills R., et al. Impact of karyotype on treatment outcome in acute myeloid leukemia. Ann Hematol 2004, 83(suppl 1):S45-S48.
19. Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006, 135:165-173.
20. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116:354-365.
21. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
22. Bello C., Yu D., Komrokji R.S., et al. Outcomes after induction chemotherapy in patients with acute myeloid leukemia arising from myelodysplastic syndrome. Cancer 2011, 117:1463-1469.
23. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98:1752-1759.
24. Verhaak R.G., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106:3747-3754.
25. Falini B., Nicoletti I., Martelli M.F., et al. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007, 109:874-885.
26. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358:1909-1918.
27. Nerlov C. C/EBPalpha mutations in acute myeloid leukaemias. Nat Rev Cancer 2004, 4:394-400.
28. Estey E.H. Therapeutic options for acute myelogenous leukemia. Cancer 2001, 92:1059-1073.
29. Bishop J.F. The treatment of adult acute myeloid leukemia. Semin Oncol 1997, 24:57-69.
30. Ohtake S., Miyawaki S., Fujita H., et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 study. Blood 2011, 117:2358-2365.
31. Weick J.K., Kopecky K.J., Appelbaum F.R., et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996, 88:2841-2851.
32. Bishop J.F., Matthews J.P., Young G.A., et al. A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 1996, 87:1710-1717.
33. Kern W., Haferlach T., Schoch C., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 trial. Blood 2003, 101:64-70.
34. Cassileth P.A., Harrington D.P., Hines J.D., et al. Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J Clin Oncol 1988, 6:583-587.
35. Yanada M., Matsuo K., Emi N., et al. Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission: a metaanalysis. Cancer 2005, 103:1652-1658.
36. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 2009, 301:2349-2361.
37. Cassileth P.A., Harrington D.P., Appelbaum F.R., et al. Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 1998, 339:1649-1656.
38. Tsimberidou A.M., Stavroyianni N., Viniou N., et al. Comparison of allogeneic stem cell transplantation, high-dose cytarabine, and autologous peripheral stem cell transplantation as postremission treatment in patients with de novo acute myelogenous leukemia. Cancer 2003, 97:1721-1731.
39. Breems D.A., Van Putten W.L., Huijgens P.C., et al. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol 2005, 23:1969-1978.
40. Craddock C., Tauro S., Moss P., et al. Biology and management of relapsed acute myeloid leukaemia. Br J Haematol 2005, 129:18-34.
41. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
42. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
43. Prébet T., Boissel N., Reutenauer S., et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009, 27:4747-4753.
44. Letendre L., Noel P., Litzow M.R., et al. Treatment of acute myelogenous leukemia in the older patient with attenuated high-dose ara-C. Am J Clin Oncol 1998, 21:142-144.
45. Sudan N., Rossetti J.M., Shadduck R.K., et al. Treatment of acute myelogenous leukemia with outpatient azacitidine. Cancer 2006, 107:1839-1843.
46. Mayer R.J., Davis R.B., Schiffer C.A., et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994, 331:896-903.
47. Stone R.M., Berg D.T., George S.L., et al. Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine. Blood 2001, 98:548-553.
48. Bertz H., Potthoff K., Finke J. Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003, 21:1480-1484.
49. Hegenbart U., Niederwieser D., Sandmaier B.M., et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006, 24:444-453.
50. Mertens A.C., Wen W., Davies S.M., et al. Congenital abnormalities in children with acute leukemia: a report from the children's Cancer Group. J Pediatr 1998, 133:617-623.
51. Chessells J.M., Harrison G., Richards S.M., et al. Down's syndrome and acute lymphoblastic leukaemia: clinical features and response to treatment. Arch Dis Child 2001, 85:321-325.
52. Toledano S.R., Lange B.J. Ataxia-telangiectasia and acute lymphoblastic leukemia. Cancer 1980, 45:1675-1678.
53. Shaw M.P., Eden O.B., Grace E., et al. Acute lymphoblastic leukemia and Klinefelter's syndrome. Pediatr Hematol Oncol 1992, 9:81-85.
54. Greaves M.F., Alexander F.E. An infectious etiology for common acute lymphoblastic leukemia in childhood?. Leukemia 1993, 7:349-360.
55. Mahieux R., Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol 2003, 7:336-361.
56. Boucheix C., David B., Sebban C., et al. Immunophenotype of adult acute lymphoblastic leukemia, clinical parameters, and outcome: an analysis of a prospective trial including 562 tested patients (LALA87). French Group on Therapy for Adult Acute Lymphoblastic Leukemia. Blood 1994, 84:1603-1612.
57. Terstappen L.W., Huang S., Picker L.J. Flow cytometric assessment of human T-cell differentiation in thymus and bone marrow. Blood 1992, 79:666-677.
58. Pullarkat V., Slovak M.L., Kopecky K.J., et al. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood 2008, 111:2563-2572.
59. Moorman A.V., Harrison C.J., Buck G.A., et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood 2007, 109:3189-3197.
60. Harrison C.J., Moorman A.V., Broadfield Z.J., et al. Three distinct subgroups of hypodiploidy in acute lymphoblastic leukaemia. Br J Haematol 2004, 125:552-559.
61. Asnafi V., Buzyn A., Le Noir S., et al. NOTCH1/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood 2009, 113:3918-3924.
62. Harrison C.J., Moorman A.V., Barber K.E., et al. Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group study. Br J Haematol 2005, 129:520-530.
63. Hilden J.M., Frestedt J.L., Moore R.O., et al. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Blood 1995, 86:3876-3882.
64. Kühnl A., Gökbuget N., Stroux A., et al. High BAALC expression predicts chemoresistance in adult B-precursor acute lymphoblastic leukemia. Blood 2010, 115:3737-3744.
65. Rowe J.M., Buck G., Burnett A.K., et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG. Blood 2005, E2993(106):3760-3767.
66. Raff T., Gökbuget N., Lüschen S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910-915.
67. Westbrook C.A., Hooberman A.L., Spino C., et al. Clinical significance of the bcr-abl fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B study. Blood 1992, 8762(80):2983-2990.
68. Wetzler M., Dodge R.K., Mrózek K., et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia group B experience. Blood 1999, 93:3983-3993.
69. Fielding A.K. Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Haematologica 2010, 95:8-12.
70. Devaraj P.E., Foroni L., Janossy G., et al. Expression of the E2A-PBX1 fusion transcripts in t(1;19)(q23;p13) and der(19)t(1;19) at diagnosis and in remission of acute lymphoblastic leukemia with different B lineage immunophenotypes. Leukemia 1995, 9:821-825.
71. Meyer C., Kowarz E., Hofmann J., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23:1490-1499.
72. Hoelzer D., Thiel E., Löffler H., et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood 1988, 71:123-131.
73. Lazarus H.M., Richards S.M., Chopra R., et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG. Blood 2006, E2993(108):465-472.
74. Brüggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
75. Larson R.A., Dodge R.K., Burns C.P., et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood 1995, 85:2025-2037.
76. Kantarjian H.M., O'Brien S., Smith T.L., et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000, 18:547-561.
77. Thomas D.A., O'Brien S., Faderl S., et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010, 28:3880-3889.
78. Bassan R., Rossi G., Pogliani E.M., et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol 2010, 28:3644-3652.
79. Yanada M., Takeuchi J., Sugiura I., et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed bcr-abl-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 2006, 24:460-466.
80. Surapaneni U.R., Cortes J.E., Thomas D., et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer 2002, 94:773-779.
81. Pullen J., Boyett J., Shuster J., et al. Extended triple intrathecal chemotherapy trial for prevention of CNS relapse in good-risk and poor-risk patients with B-progenitor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1993, 11:839-849.
82. Thiebaut A., Vernant J.P., Degos L., et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol Lala 87. Hematol/Oncol Clin North Am 2000, 14:1353-1366. x.
83. Goldstone A.H., Richards S.M., Lazarus H.M., et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL trial (MRC UKALL XII/ECOG E2993). Blood 2008, 111:1827-1833.
84. Yamamoto J.F., Goodman M.T. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer Causes Control 2008, 19:379-390.
85. Rodeghiero F., Avvisati G., Castaman G., et al. Early deaths and anti-hemorrhagic treatments in acute promyelocytic leukemia. A GIMEMA retrospective study in 268 consecutive patients. Blood 1990, 75:2112-2117.
86. Warrell S.R., Frankel W.H., Miller R.P., et al. Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991, 324:1385-1393.
87. Asou N., Adachi K., Tamura J., et al. Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. J Clin Oncol 1998, 16:78-85. Japan Adult Leukemia Study Group.
88. Fenaux P., Le Deley M.C., Castaigne S., et al. Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 group. Blood 1993, 82:3241-3249.
89. de la Serna J., Montesinos P., Vellenga E., et al. Causes and prognostic factors of remission induction failure in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and idarubicin. Blood 2008, 111:3395-3402.
90. Powell B.L., Moser B., Stock W., et al. Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American leukemia intergroup study. Blood 2010, 116:3751-3757.